转移性非小细胞肺癌的转移轨迹指导局部与全身治疗
该综述提出「转移轨迹」概念,描述病灶、器官和患者层面反应与进展的时空动态,以刻画患者内异质性并指导适应性治疗策略。文章回顾驱动病灶差异演化的生物学基础,探讨循环肿瘤DNA和影像组学等新兴生物标志物追踪轨迹演化,并提出标准化报告参数,认为将轨迹评估整合入临床可优化局部与全身治疗选择。
要点
- 转移轨迹从整体疾病状态转向单个病灶随时间的行为,刻画患者内异质性。
- 轨迹维度包括反应幅度与均匀性、耐药机制、器官趋向性及进展模式与速度。
- 循环肿瘤DNA和影像组学等或可追踪并预测轨迹演化,需标准化报告参数验证。
核心结论
- 将转移轨迹评估整合入临床实践可优化局部与全身治疗的患者选择,并实现基于生物学信息的治疗时机与强度调整。
研究设计与样本
- 综述类文章,未报告系统检索范围与样本量,提出转移轨迹框架并回顾患者内异质性的生物学基础。
主要发现
- 现有分类包括寡转移动态模型对每例患者仅赋予单一状态,无法捕捉病灶层面的异质性。
- 转移轨迹的维度包括反应幅度与均匀性、耐药机制、器官趋向性以及进展的模式、部位、范围和速度。
- 患者内异质性由基因组多样化、非遗传可塑性和肿瘤微环境适应驱动,导致病灶演化与治疗反应出现分歧。
- 循环肿瘤DNA和影像组学特征联合整合基因组与功能成像方法,或可追踪和预测轨迹演化。
关键数值与推荐
- 提出标准化报告参数以确保文档记录一致并促进跨研究验证。
- 轨迹框架支持基于观察轨迹的反应性策略和基于预测轨迹的预期性策略。
临床怎么用
- 基于轨迹的评估可用于细化局部治疗与全身治疗的患者选择。
- 可根据轨迹进行生物学信息指导的治疗时机与强度调整。
- 该框架可为面向转移性非小细胞肺癌精准管理的下一代临床试验提供基础。
局限性
- 原文未报告综述的检索范围、纳入研究数量及标准化报告参数的具体条目。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advances in systemic therapy have improved outcomes for metastatic non-small cell lung cancer (NSCLC), yet resistance and progression remain nearly universal. Local therapies such as radiotherapy, surgery, and image-guided ablation can extend disease control in selected patients, but existing classifications-including dynamic models of oligometastatic disease-assign a single state per patient and do not capture lesion-level heterogeneity. We introduce the concept of metastatic trajectories-the spatiotemporal dynamics of response and progression across lesions, organs, and patients-as a framework to characterize intrapatient heterogeneity and inform adaptive treatment strategies. Dimensions of metastatic trajectories include the magnitude and homogeneity of response, mechanisms of resistance, organotropism, and the pattern, site, extent, and pace of progression. This framework shifts the focus from overall disease states to individual lesion behavior over time, enabling reactive strategies based on observed trajectories and anticipatory strategies based on predicted ones. We review the biological foundations of intrapatient heterogeneity-including genomic diversification, nongenetic plasticity, and tumor-microenvironmental adaptation-that drive divergent lesion evolution and treatment response. Emerging biomarkers such as circulating tumor DNA and radiomic signatures, together with integrative genomic and functional imaging approaches, may allow tracking and prediction of trajectory evolution. Standardized reporting parameters are proposed to ensure consistent documentation and facilitate validation across studies. Integrating trajectory-based assessment into clinical practice could refine patient selection for local and systemic therapy, enable biology-informed adaptation of treatment timing and intensity, and provide a foundation for next-generation clinical trials aimed at precision management of metastatic NSCLC.
引用
- Willmann J, Dee EC, Hendriks LEL, et al. Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies. J Clin Oncol. 2026. PMID: 42085620. doi:10.1200/JCO-25-01958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。